Global Blood Therapeutics Inc
NASDAQ:GBT
Global Blood Therapeutics Inc
NASDAQ:GBT
Price:
68.49 USD
Market Closed
Updated:
May 7, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of GBT.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GBT
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
GBT Competitors Multiples
Global Blood Therapeutics Inc Competitors
Global Blood Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Global Blood Therapeutics Inc
NASDAQ:GBT
|
4.6B USD | 19.6 | -14.3 | -15.9 | -15.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
286.9B USD | 5.3 | 59.5 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
161B USD | 5.5 | 42.8 | 18.2 | 30 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
105.9B USD | 10.7 | 29.2 | 23.5 | 24.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.1B USD | 8.1 | 27.5 | 22.2 | 24.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.9B USD | 3 | 169.3 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.7B USD | 8.9 | -7.7 | -8.3 | -7.3 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.3 | 27.1 | 13.9 | 17.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.2 | 46 | 63.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
